Scientists at the National Institutes of Health have recently found that biologic age, or a DNA-based estimate of a person’s age, is associated with future development of breast cancer.
Scientists at the National Institutes of Health (NIH) have recently found that biologic age, or a DNA-based estimate of a person’s age, is associated with future development of breast cancer.
A person’s age is one of the “strongest predictions of cancer, chronic disease, and mortality, but biologic responses to aging differ among people,” wrote the study authors. Investigators measured baseline blood DNA methylation of 2764 women enrolled in the study who were cancer free at the time of blood collection and found that 1566 subsequently developed breast cancer after an average time frame of 6 years.
Biological age acceleration was defined for each woman by comparing her estimated biological age with her chronological age. The authors utilized 3 methylation-based “clocks” previously developed by other researchers to determine the biological age acceleration for each participant. The clocks work by measuring methylation found at specific locations within DNA. The study demonstrated that for every 5 years that a woman’s biologic age was older than her chronologic age, she had a 15% increase in her chance of developing breast cancer.
“We found that if your biologic age is older than your chronologic age, your breast cancer risk is increased. The converse was also true. If your biologic age is younger than your chronologic age, you may have decreased risk of developing breast cancer,” said Jack Taylor, MD, PhD, head of the National Institute of Environmental Health Sciences Molecular and Genetic Epidemiology Group and corresponding author of the study, in a press release.
The study was able to conclude that using DNA methylation to measure biologic age may help future researchers better understand and identify specific patients at risk of developing cancer and other age-related diseases. The research team plans to continue using epigenetic data, as well as information on genetics, environment, and lifestyle factors, to better understand how they contribute to disease risks.
Reference
Kresovich J, Xu Z, O’Brien K, Weinberg C, Sandler D, Taylor J. Methylation-based biological age and breast cancer risk [published online February 22, 2019]. J Nat Cancer Inst. doi: 10.1093/jnci/djz020.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Obesity at Cancer Diagnosis Linked to Worse Survival Outcomes in Pediatric Patients
January 13th 2025Pediatric patients considered obese at cancer diagnosis are linked to significantly worse survival outcomes, especially those with acute lymphoblastic leukemia and central nervous system tumors.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
FDA Approves Tislelizumab-jsgr as First-Line Therapy for HER2– Gastric Cancers
January 2nd 2025Tislelizumab-jsgr (Tevimbra) was approved in combination with chemotherapy for the treatment of unresectable or metastatic HER2-negative (HER–) gastric or gastroesophageal junction adenocarcinoma (G/GEJ) in adults whose tumors express PD-L1.
Read More